3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Recurrence
2
Lymphoma, B-Cell
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Liver Neoplasms
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Erectile Dysfunction
1
Carcinoma, Hepatocellular
1
Interventions
Bevacizumab
69
atezolizumab
54
lenvatinib
42
durvalumab
42
Nivolumab
38
pembrolizumab
35
tremelimumab
28
Magnetic Resonance Spectroscopy
21
Specimen Handling
19
tislelizumab
18
sintilimab
17
Ipilimumab
15
Sorafenib
14
regorafenib
13
cabozantinib
13
Radiosurgery
13
Radiotherapy
12
apatinib
11
Blood Specimen Collection
11
Immunoglobulin G
10
camrelizumab
9
Immune Checkpoint Inhibitors
9
Disulfides
9
X-Rays
8
Cyclophosphamide
8
donafenib
7
Oxaliplatin
7
Immunotherapy
7
Folfox protocol
7
Fluorouracil
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Cell- and Tissue-Based Therapy
×
1 year
×
Clear all
NCT06084884
2026-05-22
ATHENA
AstraZeneca
Phase 1/2
Active not recruiting
94 enrolled